37178-37-3 Usage
Description
Ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate, also known as L-Dopa ethyl ester, is a synthetic compound derived from the natural amino acid L-Dopa. It is characterized by its unique chemical structure, featuring a 2S configuration and a 3,4-dihydroxyphenyl group. This molecule has been found to have significant biological activities and potential therapeutic applications.
Uses
Used in Antiparkinsonian Applications:
Ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate is used as a therapeutic agent for the treatment of Parkinson's disease (PD). It serves as a precursor to dopamine, a neurotransmitter that is deficient in the brains of PD patients. By increasing dopamine levels, it helps alleviate the motor symptoms associated with the disease, such as tremors, rigidity, and bradykinesia.
Used in Neuroprotective Studies:
In the field of neuroscience, ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate is used as a research tool to study the protective effects of various compounds on neurodegenerative diseases. For instance, it has been used to investigate the neuroprotective effects of piperlongumine (PLG) on rotenone-induced Parkinson's disease models. This application aids in understanding the underlying mechanisms of neurodegeneration and the development of novel therapeutic strategies.
Used in Drug Delivery Systems:
Ethyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate can also be employed in the development of drug delivery systems, particularly for targeted delivery to the central nervous system. Its chemical properties allow for potential conjugation with various carriers, such as nanoparticles or liposomes, to enhance its bioavailability and therapeutic efficacy in treating neurological disorders.
Biochem/physiol Actions
L-Dopa ethyl ester is a prodrug of levodopa that has greater gastric solubility. The drug is rapidly hydrolyzed to levodopa by nonspecific esterases in the gastrointestinal tract. L-Dopa ethyl ester (etilevodopa)-carbidopa treatment was well tolerated but did not demonstrate better efficacy compared with standard levodopa-carbidopa treatment. L-Dopa ethyl ester should have a significant brain penetration following an administration by injection.
Check Digit Verification of cas no
The CAS Registry Mumber 37178-37-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,7,1,7 and 8 respectively; the second part has 2 digits, 3 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 37178-37:
(7*3)+(6*7)+(5*1)+(4*7)+(3*8)+(2*3)+(1*7)=133
133 % 10 = 3
So 37178-37-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H15NO4/c1-2-16-11(15)8(12)5-7-3-4-9(13)10(14)6-7/h3-4,6,8,13-14H,2,5,12H2,1H3/t8-/m0/s1
37178-37-3Relevant articles and documents
An alternative approach to the synthesis of the three fragments of anachelin H
Gamba-Sánchez, Diego,Garzón-Posse, Fabián,Prunet, Jo?lle
, p. 2702 - 2715 (2020/04/17)
The synthesis of the fully protected peptide, polyketide and alkaloid fragments of anachelin H is presented. The peptide fragment was prepared using a liquid phase peptide synthesis; the polyketide fragment was synthetized using a cross metathesis and an intramolecular oxa-Michael reaction as the key steps to introduce the desired stereochemistry; finally, the alkaloid fragment was obtained by an oxidative cyclization of a catechol derivative using potassium ferricyanide. The synthesis of all fragments was based on the use of natural amino acids as sources of asymmetry. The independent synthesis of the three fragments should allow more efficient biological studies on the fragments instead of the whole natural product. Experiments to illustrate the coupling of fragments and the effectiveness of the convergent strategy are also described.
NO-CARRIER-ADDED NUCLEOPHILIC [F-18] FLUORINATION OF AROMATIC COMPOUNDS
-
Page/Page column 18, (2010/11/03)
Phenyliodonium ylide derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are shown for use as precursors in aromatic nucleophilic substitution reactions. The iodonium ylide group is substituted by nucleophiles such as halide ions to provide the corresponding haloaryl derivatives. No- carrier-added [F-18]fluoride ion exclusively substitutes the iodonium ylide moiety in these derivatives and provides high specific activity F- 18 labeled fluoro derivatives. Protected L-dopa-6-iodonium ylide derivative have been synthesized as a precursors for the preparation of no-carrier-added 6-[F- 18]fluoro-L-dopa. The iodonium ylide group in this L-dopa.derivative is nucleophilically substituted by no-carrier-added [F-18]fluoride ion to provide a [F-18]fluoro intermediates which upon acid hydrolysis yielded 6-[F- 18]fluoro-L-dopa.
L-DOPA ethyl ester to treat Parkinson's disease
-
, (2008/06/13)
Patients suffering from Parkinson's disease are treated by administering a composition which contains an active ingredient and a pharmaceutically acceptable carrier. The active ingredient comprises L-DOPA ethyl ester in an amount which is at least 97% by weight of the active ingredient and L-DOPA in an amount which is less than 1% by weight of the active ingredient.